Troupin A, Ojemann L M, Halpern L, Dodrill C, Wilkus R, Friel P, Feigl P
Neurology. 1977 Jun;27(6):511-9. doi: 10.1212/wnl.27.6.511.
In a double-blind crossover study, carbamazepine and phenytoin were compared as single anticonvulsants in 47 patients with focal and major generalized seizures. Each drug provided superior seizure control in about half the patients, but significantly fewer patients had objective side effects while taking carbamazepine. Neuropsychologic testing showed improved performance in cognitive function and emotional status of patients while and carbamazepine. No hematotoxic complications arose, but vigilant follow-up is advised. Mean serum level of carbamazepine was 9.3 microng per milliliter with a suggested therapeutic range of 8 to 12 microng per milliliter reached by eventual doses of 16 to 20 mg per kilogram. Carbamazepine offers an independent choice of improved seizure control with a possibility of fewer side effects.
在一项双盲交叉研究中，对47例局灶性和全身性癫痫大发作患者，比较了卡马西平和苯妥英作为单一抗惊厥药物的疗效。每种药物在约一半的患者中提供了更好的癫痫控制，但服用卡马西平的患者出现客观副作用的明显较少。神经心理学测试显示，服用卡马西平期间患者的认知功能和情绪状态有所改善。未出现血液毒性并发症，但建议进行密切随访。卡马西平的平均血清水平为每毫升9.3微克，最终剂量为每公斤16至20毫克时达到建议的治疗范围每毫升8至12微克。卡马西平为改善癫痫控制提供了一种独立的选择，且副作用可能较少。
